Vincristine-laden platelet transfusion for patients with refractory thrombocytopenia

Apar Kishor P Ganti, James D. Landmark, Anne Kessinger, Lynette M Smith, Stefano R. Tarantolo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The aim of the present study was to assess they efficacy of vincristine-laden platelet transfusion for patients with refractory thrombocytopenia. Patients and methods: Twenty evaluable patients who received vincristine-laden platelets for refractory thrombocytopenia were included in this retrospective study. Vincristine (1 mg) was added to the platelets and incubated for one hour prior to transfusion. Serial platelet counts following vincristine-laden platelet transfusion and units of platelets transfused in the week prior to and the week after transfusion of vincristine-laden platelets were evaluated. Results: The underlying diseases of the patients were lung cancer (n=4), breast cancer following autologous hematopoietic stem cell transplantation and acute myeloid leukemia (n=3 each), myelodysplastic syndrome (n=2), acute lymphoid leukemia, chronic lymphoid leukemia, chronic myeloid leukemia, multiple myeloma, ovarian cancer, aspergillosis, cytomegalovirus infection and systemic lupus erythematosus (n=1 each). The median rate of change of platelet count after transfusion of vincristine-laden platelets was 550/μL/day (range, -1,000 to 12,800/μL/day; p=0.003). The median change in the number of units of platelets transfused in the week following vincristine-laden platelet transfusion was -1.5 as compared to the week prior to the transfusion (p=0.031). Patients with a primary marrow disorder exhibited no difference in either the rate of change in platelet count or in the difference in the units of platelets transfused compared to those without a primary bone marrow disorder. Conclusion: Vincristine-laden platelet transfusion was associated with significantly increased platelet counts and a subsequent decrease in platelet transfusion.

Original languageEnglish (US)
Pages (from-to)559-564
Number of pages6
JournalIn Vivo
Volume20
Issue number4
StatePublished - Jul 1 2006

Fingerprint

Platelet Transfusion
Vincristine
Platelets
Thrombocytopenia
Refractory materials
Platelet Count
Blood Platelets
Bone Marrow
Lymphoid Leukemia
Aspergillosis
Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Cytomegalovirus Infections
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multiple Myeloma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Systemic Lupus Erythematosus
Ovarian Neoplasms
Lung Neoplasms

Keywords

  • Platelet counts
  • Refractory thrombocytopenia
  • Vincristine-laden platelet transfusion

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this

Ganti, A. K. P., Landmark, J. D., Kessinger, A., Smith, L. M., & Tarantolo, S. R. (2006). Vincristine-laden platelet transfusion for patients with refractory thrombocytopenia. In Vivo, 20(4), 559-564.

Vincristine-laden platelet transfusion for patients with refractory thrombocytopenia. / Ganti, Apar Kishor P; Landmark, James D.; Kessinger, Anne; Smith, Lynette M; Tarantolo, Stefano R.

In: In Vivo, Vol. 20, No. 4, 01.07.2006, p. 559-564.

Research output: Contribution to journalArticle

Ganti, AKP, Landmark, JD, Kessinger, A, Smith, LM & Tarantolo, SR 2006, 'Vincristine-laden platelet transfusion for patients with refractory thrombocytopenia', In Vivo, vol. 20, no. 4, pp. 559-564.
Ganti, Apar Kishor P ; Landmark, James D. ; Kessinger, Anne ; Smith, Lynette M ; Tarantolo, Stefano R. / Vincristine-laden platelet transfusion for patients with refractory thrombocytopenia. In: In Vivo. 2006 ; Vol. 20, No. 4. pp. 559-564.
@article{ab35b1ac04de4c079acf7d89439244e7,
title = "Vincristine-laden platelet transfusion for patients with refractory thrombocytopenia",
abstract = "Background: The aim of the present study was to assess they efficacy of vincristine-laden platelet transfusion for patients with refractory thrombocytopenia. Patients and methods: Twenty evaluable patients who received vincristine-laden platelets for refractory thrombocytopenia were included in this retrospective study. Vincristine (1 mg) was added to the platelets and incubated for one hour prior to transfusion. Serial platelet counts following vincristine-laden platelet transfusion and units of platelets transfused in the week prior to and the week after transfusion of vincristine-laden platelets were evaluated. Results: The underlying diseases of the patients were lung cancer (n=4), breast cancer following autologous hematopoietic stem cell transplantation and acute myeloid leukemia (n=3 each), myelodysplastic syndrome (n=2), acute lymphoid leukemia, chronic lymphoid leukemia, chronic myeloid leukemia, multiple myeloma, ovarian cancer, aspergillosis, cytomegalovirus infection and systemic lupus erythematosus (n=1 each). The median rate of change of platelet count after transfusion of vincristine-laden platelets was 550/μL/day (range, -1,000 to 12,800/μL/day; p=0.003). The median change in the number of units of platelets transfused in the week following vincristine-laden platelet transfusion was -1.5 as compared to the week prior to the transfusion (p=0.031). Patients with a primary marrow disorder exhibited no difference in either the rate of change in platelet count or in the difference in the units of platelets transfused compared to those without a primary bone marrow disorder. Conclusion: Vincristine-laden platelet transfusion was associated with significantly increased platelet counts and a subsequent decrease in platelet transfusion.",
keywords = "Platelet counts, Refractory thrombocytopenia, Vincristine-laden platelet transfusion",
author = "Ganti, {Apar Kishor P} and Landmark, {James D.} and Anne Kessinger and Smith, {Lynette M} and Tarantolo, {Stefano R.}",
year = "2006",
month = "7",
day = "1",
language = "English (US)",
volume = "20",
pages = "559--564",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Vincristine-laden platelet transfusion for patients with refractory thrombocytopenia

AU - Ganti, Apar Kishor P

AU - Landmark, James D.

AU - Kessinger, Anne

AU - Smith, Lynette M

AU - Tarantolo, Stefano R.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Background: The aim of the present study was to assess they efficacy of vincristine-laden platelet transfusion for patients with refractory thrombocytopenia. Patients and methods: Twenty evaluable patients who received vincristine-laden platelets for refractory thrombocytopenia were included in this retrospective study. Vincristine (1 mg) was added to the platelets and incubated for one hour prior to transfusion. Serial platelet counts following vincristine-laden platelet transfusion and units of platelets transfused in the week prior to and the week after transfusion of vincristine-laden platelets were evaluated. Results: The underlying diseases of the patients were lung cancer (n=4), breast cancer following autologous hematopoietic stem cell transplantation and acute myeloid leukemia (n=3 each), myelodysplastic syndrome (n=2), acute lymphoid leukemia, chronic lymphoid leukemia, chronic myeloid leukemia, multiple myeloma, ovarian cancer, aspergillosis, cytomegalovirus infection and systemic lupus erythematosus (n=1 each). The median rate of change of platelet count after transfusion of vincristine-laden platelets was 550/μL/day (range, -1,000 to 12,800/μL/day; p=0.003). The median change in the number of units of platelets transfused in the week following vincristine-laden platelet transfusion was -1.5 as compared to the week prior to the transfusion (p=0.031). Patients with a primary marrow disorder exhibited no difference in either the rate of change in platelet count or in the difference in the units of platelets transfused compared to those without a primary bone marrow disorder. Conclusion: Vincristine-laden platelet transfusion was associated with significantly increased platelet counts and a subsequent decrease in platelet transfusion.

AB - Background: The aim of the present study was to assess they efficacy of vincristine-laden platelet transfusion for patients with refractory thrombocytopenia. Patients and methods: Twenty evaluable patients who received vincristine-laden platelets for refractory thrombocytopenia were included in this retrospective study. Vincristine (1 mg) was added to the platelets and incubated for one hour prior to transfusion. Serial platelet counts following vincristine-laden platelet transfusion and units of platelets transfused in the week prior to and the week after transfusion of vincristine-laden platelets were evaluated. Results: The underlying diseases of the patients were lung cancer (n=4), breast cancer following autologous hematopoietic stem cell transplantation and acute myeloid leukemia (n=3 each), myelodysplastic syndrome (n=2), acute lymphoid leukemia, chronic lymphoid leukemia, chronic myeloid leukemia, multiple myeloma, ovarian cancer, aspergillosis, cytomegalovirus infection and systemic lupus erythematosus (n=1 each). The median rate of change of platelet count after transfusion of vincristine-laden platelets was 550/μL/day (range, -1,000 to 12,800/μL/day; p=0.003). The median change in the number of units of platelets transfused in the week following vincristine-laden platelet transfusion was -1.5 as compared to the week prior to the transfusion (p=0.031). Patients with a primary marrow disorder exhibited no difference in either the rate of change in platelet count or in the difference in the units of platelets transfused compared to those without a primary bone marrow disorder. Conclusion: Vincristine-laden platelet transfusion was associated with significantly increased platelet counts and a subsequent decrease in platelet transfusion.

KW - Platelet counts

KW - Refractory thrombocytopenia

KW - Vincristine-laden platelet transfusion

UR - http://www.scopus.com/inward/record.url?scp=33746875149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746875149&partnerID=8YFLogxK

M3 - Article

C2 - 16900790

AN - SCOPUS:33746875149

VL - 20

SP - 559

EP - 564

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 4

ER -